Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

20 luglio 2026 aggiornato da: ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IMC-003 Injection in Patients With Pulmonary Arterial Hypertension (PAH) Receiving Background Therapy.

This is a Phase Ib/IIa clinical study of IMC-003 treatment in pulmonary arterial hypertension (PAH) patients receiving background therapy

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Stimato)

120

Fase

  • Fase 2
  • Fase 1

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

  • Cina
    • Beijing Municipality
      • Beijing, Beijing Municipality, Cina
        • Non ancora reclutamento
        • Xuanwu Hospital Capital Medical University
        • Contatto:
    • Changchun
      • Jilin City, Changchun, Cina
        • Reclutamento
        • The First Hospital of Jilin University
        • Contatto:
    • Fujian
      • Fuzhou, Fujian, Cina
        • Non ancora reclutamento
        • Fujian Medical University Union Hospita
        • Contatto:
      • Xiamen, Fujian, Cina
        • Reclutamento
        • Xiamen Hospital of T.C.M.
        • Contatto:
    • Gansu
      • Lanzhou, Gansu, Cina
        • Reclutamento
        • GanSu Provincial Hospital
        • Contatto:
    • Guangdong
      • Guangzhou, Guangdong, Cina
        • Reclutamento
        • Guangdong Provincial People's Hospital
        • Contatto:
          • Xin Jang, M.D.
          • Numero di telefono: 86+15910646886
          • Email: jxcs83@163.com
    • Guizhou
      • Guiyang, Guizhou, Cina
        • Non ancora reclutamento
        • The Affiliated Hospital of Guizhou Medical University
        • Contatto:
    • Henan
      • Zhengzhou, Henan, Cina
        • Reclutamento
        • The First Affiliated Hospital of Zhengzhou University
        • Contatto:
      • Zhengzhou, Henan, Cina
        • Non ancora reclutamento
        • Fuwai Center China Cardiovascular Hospital
        • Contatto:
    • Hubei
      • Wuhan, Hubei, Cina
        • Non ancora reclutamento
        • Zhongnan Hospital of Wuhan University
        • Contatto:
      • Wuhan, Hubei, Cina
        • Reclutamento
        • Wuhan Asia Heart Hospital
        • Contatto:
    • Hunan
      • Changsha, Hunan, Cina
        • Non ancora reclutamento
        • The Second Xiangya Hospital of Central South University
        • Contatto:
    • Jiangsu
      • Xuzhou, Jiangsu, Cina
        • Reclutamento
        • Xuzhou Central Hospital
        • Contatto:
    • Jiangxi
      • Nanchang, Jiangxi, Cina
        • Non ancora reclutamento
        • The First Affiliated Hospital of Nanchang University
        • Contatto:
    • Liaoning
      • Shenyang, Liaoning, Cina
        • Non ancora reclutamento
        • General Hospital of the Northern Theater Command
        • Contatto:
    • Shangdong
      • Jinan, Shangdong, Cina
        • Reclutamento
        • Qilu Hospital of Shandong University
        • Contatto:
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina
        • Non ancora reclutamento
        • Shanghai Pulmonary Hospital
        • Contatto:
      • Shanghai, Shanghai Municipality, Cina
        • Reclutamento
        • Shanghai Tongji Hospital
        • Contatto:
      • Shanghai, Shanghai Municipality, Cina
        • Non ancora reclutamento
        • Shanghai Chest Hospital
        • Contatto:
    • Sichuan
      • Chengdu, Sichuan, Cina
        • Non ancora reclutamento
        • West China Hospital, Sichuan University
        • Contatto:
      • Chengdu, Sichuan, Cina
        • Non ancora reclutamento
        • Sichuan Provincial People's Hospital
        • Contatto:
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina
        • Non ancora reclutamento
        • The Second Hospital of Tianjin Medical University
        • Contatto:
      • Tianjin, Tianjin Municipality, Cina
        • Reclutamento
        • Tianjin Medical University General Hospital
        • Contatto:
    • Yunnan
      • Kunming, Yunnan, Cina
        • Non ancora reclutamento
        • Kunming Yan'an Hospital
        • Contatto:
    • Zhejiang
      • Hangzhou, Zhejiang, Cina
        • Non ancora reclutamento
        • The First Affiliated Hospital of Zhejiang University school of medicine
        • Contatto:
      • Hangzhou, Zhejiang, Cina
        • Reclutamento
        • The Second Affiliated Hospital Zhejiang University School of Medicine
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Participants aged 18-75 years old (inclusive), any gender;

  2. Patients diagnosed with WHO Group 1 pulmonary arterial hypertension (PAH) via right heart catheterization (RHC) before dosing (see Appendix 1), including the following subtypes:

    • Idiopathic PAH;
    • Heritable PAH;
    • Drug- or toxin-induced PAH;
    • Inactive, connective tissue disease-associated PAH;
    • Simple congenital heart disease with left-to-right shunt-related PAH, at least 1 year post-repair surgery;
  3. Symptomatic pulmonary arterial hypertension, WHO functional class II or III ;

  4. Must also meet the following hemodynamic criteria:

    • Mean pulmonary arterial pressure (mPAP) at rest ≥25 mmHg;
    • Pulmonary arterial wedge pressure (PAWP) ≤15 mmHg;
  5. Pulmonary vascular resistance (PVR) measured by RHC within 10 days before initial dosing ≥5 Wood Units (400 dyn·sec·cm-5), prior RHC results before screening are acceptable if they meet study requirements;

  6. Receiving stable doses of background PAH therapy (i.e., for at least 90 days before first dosing, individualized target doses for each therapy reached and stable); for subcutaneous prostacyclin users, a 10% variation around the optimal dose is allowed following medical practice, detailed as follows:

    • Background PAH therapy refers to approved PAH-specific drugs, including ERA and/or PDE-5i or sGC stimulators and/or prostacyclin analogs or receptor agonists (subcutaneous). Note: PAH background therapy drugs should meet the following doses: Macitentan 10 mg qd, Ambrisentan 10 mg qd; Sildenafil ≥20 mg tid, Tadalafil 20-40 mg qd; Riociguat 2 mg or 2.5 mg tid; Selexipag 0.8-1.6 mg bid; Subcutaneous treprostinil ≥20 ng/kg/min. Note: Drugs used for acute pulmonary vasoreactivity testing are not considered background therapy.
  7. During screening and within 10 days before first dosing, the mean of two 6-minute walk distance (6MWD) tests should be ≥150m and ≤450m, with a maximum difference of 15% (based on the higher value); the two tests should be at least 4 hours apart and no longer than 1 week apart (if the difference exceeds 15%, repeat once within 4 hours to 1 week).
  8. Female participants of childbearing potential must have a negative serum pregnancy test before dosing, agree to regular urine or serum pregnancy tests during treatment (any one), use highly effective contraception before dosing, during treatment (including dosing interruption) and for 16 weeks (112 days) after the last dose, and avoid blood or egg donation for 16 weeks (112 days) after the last dose.
  9. Male participants agree to use condoms, defined as using latex condoms or non-latex condoms made from non-natural (animal) membranes (e.g., polyurethane) during sexual activity with pregnant women or women of childbearing potential during the dosing period (including any interruption) and for 16 weeks (112 days) after the last dose, even if they have successfully undergone a vasectomy, and to avoid donating sperm during this time;
  10. Participants understand and follow the study procedures, voluntarily participate, and sign the informed consent form.

Exclusion Criteria:

1) Diagnosed with WHO Group 2, 3, 4, or 5 pulmonary hypertension. 2) Diagnosed with the following PAH subtypes in WHO Group 1:

  • HIV-associated PAH
  • Portal hypertension-associated PAH
  • Schistosomiasis-associated PAH
  • PAH associated with pulmonary veno-occlusive disease or pulmonary capillary hemangiomatosis

  • PAH patients with known positive acute pulmonary vasoreactivity test 3) History of echocardiogram within 6 months before screening showing left ventricular ejection fraction <45%, or pre-dose echocardiogram showing left ventricular ejection fraction <45%, or as assessed by the investigator, acute decompensated heart failure occurring within 30 days before screening, or evidence or history of clinically significant heart disease (including but not limited to: significant (≥2+) mitral or aortic valve regurgitation, restrictive or congestive cardiomyopathy, or pericardial constriction).

    4) Poorly controlled hypertension at rest during the screening period: seated systolic BP >160 mmHg or seated diastolic BP >100 mmHg, or pre-dose systolic BP <90 mmHg on Day 1.

    5) Pre-dose ECG Fridericia corrected QT interval (QTcF) ≥470 ms for men, ≥480 ms for women, or personal/family history of long QT syndrome (LQTS) or sudden cardiac death.

    6) Any symptomatic coronary artery disease event (previous myocardial infarction, PCI, CABG, or angina), or history of cerebrovascular accident within 3 months before screening. Note: if coronary angiography shows no obstruction (lumen stenosis ≤50%), angina may not be an exclusion.

    7) Use of IV positive inotropic agents (such as dobutamine, dopamine, norepinephrine, vasopressin, milrinone, levosimendan, etc.) within 30 days before the screening visit.

    8) History of arterial or deep vein thrombosis within 6 months before dosing, or any spontaneous bleeding of any severity within 2 months before dosing.

    9) Untreated mild or more severe obstructive sleep apnea history. 10）Previous or planned heart or lung transplant, or expected lifespan <12 months as assessed by the investigator.

    11) Diagnosed with chronic obstructive pulmonary disease (COPD) or other clinically significant lung diseases.

    12) Exclusion if there is evidence of interstitial lung disease (ILD) from a chest CT within 1 year before screening or a lung function test (PET) within 6 months before screening; if these test results are not available, or if the chest CT within 1 year shows mild or more severe ILD, a lung function test (PET) or chest CT must be done during the screening period, and patients with ILD detected are excluded.

    13) Before administration, hemoglobin (Hb) > the upper limit of normal (ULN) for their gender or <90 g/L, platelet count ≤100×10⁹/L, neutrophils <1.5×10⁹/L, AST or ALT >3×ULN, total bilirubin >1.5×ULN, estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m² (defined according to CKD-EPI 2021 formula).

    14) History of portal hypertension or chronic liver disease, including positive Hepatitis B surface antigen (HBsAg) and/or positive Hepatitis B core antibody (HBcAb) with HBV-DNA levels above the normal range; positive Hepatitis C virus (HCV) and positive HCV-RNA; positive HIV serology; positive Treponema pallidum antibody (TP-Ab) (if Treponema pallidum serology is positive, a non-Treponema pallidum serology test should be done, and if negative and judged by the investigator as a cured past syphilis infection, the patient can be included).

    15) Currently participating in other clinical studies; or has participated in a medical device or drug clinical study within 30 days before screening (except those who only signed the ICF but did not receive investigational drug or device intervention), or still within 5 half-lives (t1/2) of an investigational product (whichever is longer).

    16) Previously received treatment targeting the TGF-β superfamily (e.g., Sotatercept), including participation in clinical trials.

    17) Known allergies to large molecule protein products/monoclonal antibodies, the study drug or its excipients, or drugs of the same type.

    18) Started a cardiopulmonary rehabilitation exercise program within 90 days before screening, or planning to start one during the study (participants who have maintained a stable program and will continue during the study are eligible).

    19) History of opportunistic infections (e.g., invasive candidiasis or Pneumocystis pneumonia within 6 months before dosing); severe local infections (e.g., cellulitis, abscess) or systemic infections (e.g., sepsis) within 4 weeks before screening.

    20) Major surgery within 8 weeks before the first dose, or participants not fully recovered from previous surgery before the first dose.

    21) If receiving corticosteroid therapy, any of the following within 30 days before the first dose: taken >20 mg/day of prednisone (or equivalent) or started a new dose/change in dose ≤20 mg/day, the participant is excluded; stable ≤20 mg/day prednisone (or equivalent) within 30 days before the first dose is allowed. For connective tissue disease-associated pulmonary arterial hypertension patients on immunosuppressive therapy, if the treatment has been stable for less than 3 months prior to dosing; any participant who has received CRA-T therapy is excluded.

    22) History of malignancy or current malignancy (excluding basal cell carcinoma excised with no evidence of metastasis for 3 years, or treated cervical intraepithelial neoplasia with unknown recurrence status).

    23) Autoimmune disease, except for PAH etiology-related diseases included in this study.

    24) History of chronic kidney disease, or acute kidney injury requiring acute dialysis within 3 months before screening regardless of past kidney disease history.

    25) Pregnant or breastfeeding women. 26) Participants deemed unsuitable for the study by the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Comparatore attivo: Experimental: IMC-003
Subjects will receive eight injection treatments with IMC-003, once every three weeks.
Droga: IMC-003 and PAH background therapy
Subjects will receive 8 injections of IMC-003 and will also need to have stable background treatment for pulmonary arterial hypertension.
Comparatore placebo: placebo of IMC-003
Subjects will receive eight injection treatments with placebo of IMC-003, once every three weeks.
Droga: IMC-003 placebo and PAH background therapy
Subjects will receive 8 injections placebo of IMC-003 and will also need to have stable background treatment for pulmonary arterial hypertension.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase Ib
Lasso di tempo: 24 weeks

Primary Endpoints

  • Safety and Tolerability: Incidence and frequency of adverse events (AEs) and serious adverse events (SAEs) (according to CTCAE v6.0 from NCI);
  • abnormalities in vital signs, physical exams（The units for height are centimeters and for weight are kilograms ）, lab tests, 12-lead ECG, echocardiography, etc., before and after medication.

Primary Efficacy Endpoint

- Change in hemodynamic indicator pulmonary vascular resistance (PVR) from baseline at Week 24 of treatment.
24 weeks
Phase IIa
Lasso di tempo: 24 weeks

Primary efficacy endpoint:

- Change in hemodynamic parameter pulmonary vascular resistance (PVR) from baseline after 24 weeks of treatment.

Safety endpoints:

  • Occurrence and frequency of AE and SAE;
  • Any abnormalities in vital signs, physical exams（The units for height are centimeters and for weight are kilograms ）, lab tests, 12-lead ECGs, and echocardiograms before and after treatment.
24 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Proportion of participants meeting composite improvement criteria . Other hemodynamic-related changes. Changes in heart MRI-related indicators. Changes in 6MWD. Changes in WHO FC classification. Changes in NT-proBNP. The rate at which the disease worsens
Lasso di tempo: 24 weeks

  1. At 24 weeks of treatment, the proportion of participants who achieved the composite improvement criteria :

    • Six-minute walk distance increased by ≥30 meters from baseline
    • NT-proBNP decreased by ≥30% from baseline, or NT-proBNP levels remained/achieved <300 ng/L
    • WHO functional class improved by at least 1 level from baseline, or maintained at WHO FC II
  2. At 24 weeks of treatment, changes in other hemodynamic-related indicators from baseline
  3. At 24 weeks of treatment, changes in heart-related MRI indicators from baseline
  4. After treatment, assess the change in 6MWD from baseline at the end of the 2nd, 4th, 6th, and 8th treatment cycles
  5. After treatment, the change in WHO functional class from baseline at the end of each treatment cycle
  6. After treatment, the change in NT-proBNP from baseline at the end of each treatment cycle
  7. The rate of disease progression at 24 weeks of treatment
24 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.

Investigatori

  • Investigatore principale: Zhicheng Jing, M.D., Guangdong Provincial People's Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

30 aprile 2026

Completamento primario (Stimato)

31 ottobre 2027

Completamento dello studio (Stimato)

30 novembre 2027

Date di iscrizione allo studio

Primo inviato

9 maggio 2026

Primo inviato che soddisfa i criteri di controllo qualità

15 maggio 2026

Primo Inserito (Effettivo)

18 maggio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

22 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

20 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • IMC-003-Ⅱ-01

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi